An Investigator Initiated Prospective, Single Arm Observational Study to Evaluate the Safety and Efficacy of Saroglitazar 4 mg in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non- Alcoholic Steatohepatitis (NASH)

Simple item page
dc.contributor.authorHajare, Santosh Den_US
dc.contributor.authorGokak, Varadaraj Pen_US
dc.contributor.authorGhorpade, Sandeshaen_US
dc.contributor.authorPatil, Amaren_US
dc.contributor.authorJadhav, Arvinden_US
dc.date.accessioned2020-09-24T07:11:26Z
dc.date.available2020-09-24T07:11:26Z
dc.date.issued2019-12
dc.description.abstractIntroduction: Saroglitazar is known to safely and effectivelyimprove dyslipidemia by reducing triglyceride (TG), lowdensity lipoprotein (LDL) cholesterol, very low-densitylipoprotein (VLDL) cholesterol, non-high-density lipoprotein(non-HDL) cholesterol and increasing high densitylipoprotein (HDL) cholesterol. In addition, saroglitazar canimprove glycemic indices in diabetic patients by reducingfasting plasma glucose (FPG) and glycosylated haemoglobin(HbA1c). Aim of the study was to evaluate the hospital basedclinic-pathological profile, diagnosis, treatment and followup of Indian patients with Non-alcoholic fatty liver diseaseand to evaluate the safety and efficacy of Saroglitazar 4 mg inpatients with Non-alcoholic fatty liver disease /Non-alcoholicSteatohepatitis in real life setting.Material and methods: This was an ongoing observationalstudy with the sample size of 52 patients having Nonalcoholic fatty liver disease and dyslipidaemia with or withoutType 2 Diabetes Mellitus and treatment follow up for a periodof 1 year in the Department Of Gastroenterology. The datawas collected from eligible patients who have been prescribedSaroglitazar 4 mg once daily in routine clinical practice.Primary endpoints were to see liver stiffness. Secondaryendpoints were to measure serum alanine aminotransferase,aspartate aminotransferase level and Serum triglycerideslevel.Results: There was a significant decrease in Serum alanineaminotransferase (p <0.001), aspartate aminotransferase (pvalue < 0.001), triglycerides (p value <0.001) and triglycerides(p value 0.01), levels after the treatment as compared to thebaseline.Conclusion: Saroglitazar treatment is effective and there isa significant difference in Serum alanine aminotransferaseand aspartate aminotransferase, triglycerides and LiverStiffness Measurement levels after treatment. The drug can besuccessfully administered for the treatment of Non-alcoholicfatty liver disease.en_US
dc.identifier.affiliationsProfessor and HOD, Department of Gastroenterology, Jawaharlal Nehru Medical College, Department of Gastroenterology, Belagavi, Belgaum, Karnataka, Indiaen_US
dc.identifier.affiliationsAssistant Professor, Department of Gastroenterology, Jawaharlal Nehru Medical College, Department of Gastroenterology, Belagavi, Belgaum, Karnataka, Indiaen_US
dc.identifier.affiliationsMedical Officer, Department of Gastroenterology, Jawaharlal Nehru Medical College, Department of Gastroenterology, Belagavi, Belgaum, Karnataka, Indiaen_US
dc.identifier.affiliationsSenior Resident, Department of Gastroenterology, Jawaharlal Nehru Medical College, Department of Gastroenterology, Belagavi, Belgaum, Karnataka, Indiaen_US
dc.identifier.affiliationsMedical Officer, Department of Gastroenterology, Kaher, Jawaharlal Nehru Medical College, Department of Gastroenterology, Belagavi, Belgaum, Karnataka, Indiaen_US
dc.identifier.citationHajare Santosh D, Gokak Varadaraj P, Ghorpade Sandesha, Patil Amar, Jadhav Arvind. An Investigator Initiated Prospective, Single Arm Observational Study to Evaluate the Safety and Efficacy of Saroglitazar 4 mg in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non- Alcoholic Steatohepatitis (NASH). International Journal of Contemporary Medical Research . 2019 Dec; 6(12): l5-l7en_US
dc.identifier.issn2393-915X
dc.identifier.issn2454-7379
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/202725
dc.languageenen_US
dc.publisherInternational Society for Contemporary Medical Researchen_US
dc.relation.issuenumber12en_US
dc.relation.volume6en_US
dc.source.urihttps://dx.doi.org/10.21276/ijcmr.2019.6.12.35en_US
dc.subjectNon-alcoholic Fatty Liver Diseaseen_US
dc.subjectTriglyceridesen_US
dc.subjectDyslipidemiaen_US
dc.subjectInsulinen_US
dc.subjectAlanine Aminotransaminaseen_US
dc.titleAn Investigator Initiated Prospective, Single Arm Observational Study to Evaluate the Safety and Efficacy of Saroglitazar 4 mg in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non- Alcoholic Steatohepatitis (NASH)en_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcmr2019v6n12pll5.pdf
Size:
605.67 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Contemporary Medical Research